VERIGRAFT
Bioengineered, personalized vascular grafts created using advanced 3D printing and tissue engineering technologies.
- CEO / Founder
- Petter Björquist, Ph.D.
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $1.3M
- Key Investors
- Eurostars program; Vinnova
Technology & Products
Key Products
3D printed arterial grafts, Vascular grafts
Technological Advantage
Breakthrough 3D printing techniques enabling highly personalized and biocompatible grafts.
Differentiation
Value Proposition
Personalized 3D printed grafts that mimic natural arteries, offering enhanced biocompatibility, integration, and durability.
How They Differentiate
Focus on personalized, bioengineered vascular grafts with superior biocompatibility compared to conventional synthetic options.
Market & Competition
Target Customers
Medical professionals, vascular surgeons, and patients requiring vascular interventions
Industry Verticals
Healthcare, Regenerative Medicine, Tissue Engineering
Competitors
Aspect Biosystems; Miromatrix; Gore Medical
Growth & Milestones
Growth Metrics
Advancement in preclinical development towards first-in-human trials
Major Milestones
Secured €1.2M Eurostars grant for breakthrough 3D bioprinting technology, Secured SEK 6 million Vinnova grant for AI-based quality improvement in vascular graft manufacturing (Dec 2023), Raised USD 10M capital contribution from existing investors (Mar 2026) to advance P-TEV, Received CTA approval for pivotal Phase II/III trial of P-TEV (2026-05-13), Partnered with TFS HealthScience for pivotal Phase II/III P-TEV trial in chronic venous insufficiency (2026-05-28), Partnered with BBG Advanced Therapies on US market readiness for P-TEV (2026-06-24), Named finalist, Health Tech Award 2026 (2026-04-20)
Notable Customers
Sahlgrenska University Hospital